Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life Years for 29 Cancer Groups From 2010 to 2019

Abstract

and Risk Factors Study 2019 (GBD 2019) provided systematic estimates of incidence, morbidity, and mortality to inform local and international efforts toward reducing cancer burden. OBJECTIVE To estimate cancer burden and trends globally for 204 countries and territories and by Sociodemographic Index (SDI) quintiles from 2010 to 2019. EVIDENCE REVIEWThe GBD 2019 estimation methods were used to describe cancer incidence, mortality, years lived with disability, years of life lost, and disability-adjusted life years (DALYs) in 2019 and over the past decade. Estimates are also provided by quintiles of the SDI, a composite measure of educational attainment, income per capita, and total fertility rate for those younger than 25 years. Estimates include 95% uncertainty intervals (UIs).FINDINGS In 2019, there were an estimated 23.6 million (95% UI, 22.2-24.9 million) new cancer cases (17.2 million when excluding nonmelanoma skin cancer) and 10.0 million (95% UI, 9.36-10.6 million) cancer deaths globally, with an estimated 250 million (235-264 million) DALYs due to cancer. Since 2010, these represented a 26.3% (95% UI, 20.3%-32.3%) increase in new cases, a 20.9% (95% UI, 14.2%-27.6%) increase in deaths, and a 16.0% (95% UI, 9.3%-22.8%) increase in DALYs. Among 22 groups of diseases and injuries in the GBD 2019 study, cancer was second only to cardiovascular diseases for the number of deaths, years of life lost, and DALYs globally in 2019. Cancer burden differed across SDI quintiles. The proportion of years lived with disability that contributed to DALYs increased with SDI, ranging from 1.4% (1.1%-1.8%) in the low SDI quintile to 5.7% (4.2%-7.1%) in the high SDI quintile. While the high SDI quintile had the highest number of new cases in 2019, the middle SDI quintile had the highest number of cancer deaths and DALYs. From 2010 to 2019, the largest percentage increase in the numbers of cases and deaths occurred in the low and low-middle SDI quintiles. CONCLUSIONS AND RELEVANCEThe results of this systematic analysis suggest that the global burden of cancer is substantial and growing, with burden differing by SDI. These results provide comprehensive and comparable estimates that can potentially inform efforts toward equitable cancer control around the world.

Lung Cancer Screening in Asbestos-Exposed Populations

“…Lung cancer remains the most common cause of cancer mortality in the world, causing nearly one in five (20.4%) cancer deaths in 2019 [ 4 ]. A substantial proportion of all lung cancers, in the range of 10% to 15%, are caused collectively by the more than two dozen occupational exposures that are recognized lung carcinogens in humans [ 1 , 5 , 6 , 7 ].…”

Biomarker-Based Models for Preoperative Assessment of Adnexal Mass: A Multicenter Validation Study

“…Ovarian cancer (OC) accounts for 3.4% and 4.7% of new cancers and cancer-related deaths in women worldwide, with 313,959 new cases and 207,252 cancer-related deaths in 2020, respectively [ 1 ]. Globally, OC incidence, related deaths and disability-adjusted life-years doubled between 1990 and 2020 [ 1 , 2 , 3 ]. The overall mortality attributed to OC exceeds that of any other gynecological cancer [ 1 , 2 , 3 ].…”

“…Globally, OC incidence, related deaths and disability-adjusted life-years doubled between 1990 and 2020 [ 1 , 2 , 3 ]. The overall mortality attributed to OC exceeds that of any other gynecological cancer [ 1 , 2 , 3 ]. This deadliest amongst all genital cancers will develop in 1.1–1.5% of women during their lifespan [ 1 , 2 , 3 ].…”

“…The overall mortality attributed to OC exceeds that of any other gynecological cancer [ 1 , 2 , 3 ]. This deadliest amongst all genital cancers will develop in 1.1–1.5% of women during their lifespan [ 1 , 2 , 3 ]. The high mortality rates result from usually advanced stages at diagnosis (70% of OC are diagnosed in FIGO stage III/IV), the high biological aggressiveness of the most common histological subtype (high-grade serous OC (HGSOC) accounting for 75% of all ovarian malignancies) and the lack of effective screening strategies [ 2 , 3 , 4 , 5 ].…”

miR-488-3p Protects Cardiomyocytes against Doxorubicin-Induced Cardiotoxicity by Inhibiting CyclinG1

“…Although cancer incidence and mortality have decreased in recent years, they still pose a serious threat to various physiological and behavioral processes. Statistics show that the number of new cases of cancer remains a challenge for the medical community each year [ 1 ]. Cancer is one of the leading causes of global death [ 2 ].…”